Testing different ways to give bimekizumab for psoriatic arthritis or axial spondyloarthritis
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have active psoriatic arthritis or axial spondyloarthritis that is suitable for bimekizumab treatment.
- Your weight is between 45 and 100 kg (if female) or 50 and 100 kg (if male).
- You have either never taken a biologic drug for your condition, or you stopped taking one at least 3 months or 5 half-lives ago.
- You do not have serious organ problems (like heart, liver, kidney), severe mental health issues, or recent infections (including tuberculosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
This trial tests different targeted treatments for people with rheumatoid arthritis who have tried one or two biologic or targeted synthetic drugs but still have symptoms. You need to be taking a stable dose of methotrexate.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.